67.37USD-2.09%Mkt Cap: 5.62B USDP/E: —Last update: 2026-05-26
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. T…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap5.62B USD
Enterprise Value6.62B USD
Revenue (TTM)827.11M USD
Gross Profit1.68B USD
Net Income (TTM)682.64M USD
Revenue/Share10.26 USD
Last Price67.37 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees991
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)25.07
PEG—
EV/EBITDA-316.68
EV/Revenue8.00
P/S7.00
P/B-27.69
EPS (TTM)-2.54
EPS (Forward)2.78
52W Range
43.1755% of range87.50
52W High87.50 USD
52W Low43.17 USD
Profitability
Gross Margin97.28%
Oper. Margin16.54%
EBITDA Margin-2.53%
Profit Margin39.44%
ROE-332.49%
ROA23.55%
Growth
Revenue Growth-76.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF711.20M USD
CapEx (TTM)300.01M USD
FCF Margin-50.55%
FCF Yield-7.44%
Net Debt829.85M USD
Net Debt/EBITDA-39.70
Balance Sheet
Debt/Equity-13.19
Current Ratio2.44
Quick Ratio2.29
Book Value/Sh-2.5200 USD
Cash/Share22.82 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.1 (Buy)
Target (Mean)90.93 USD
Target Range65.00 USD – 124.00 USD
# Analysts14
Ownership
Shares Out.82.95M
Float73.16M
Insiders7.38%
Institutions117.88%
Short Interest
Short Ratio9.2d
Short % Float15.99%
Short % Out.11.77%
Shares Short9.76M
Short (prev mo.)9.45M
Technical
SMA 5068.88 (-2.2%)
SMA 20068.03 (-1.0%)
Beta0.53
S&P 52W Chg28.31%
Avg Vol (30d)1.34M
Avg Vol (10d)1.74M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—